Mexico Angioplasty Balloons Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Mexico Angioplasty Balloons Market Size

• The Mexico Angioplasty Balloons Market size was valued at USD 27.73 Million in 2025and is expected to reach USD 38.99 Million by 2033, at a CAGR of 4.4% during the forecast period
• Angioplasty balloons are specialized medical devices used in minimally invasive cardiovascular procedures to restore blood flow in narrowed or blocked arteries. They are mounted on the tip of a catheter and guided to the affected area through the vascular system, typically during a percutaneous coronary intervention.

Mexico Angioplasty Balloons Market Analysis

• The Mexico angioplasty balloons market represents a vital segment within the country’s cardiovascular medical devices industry, supporting interventional cardiology procedures across hospitals, specialty clinics, and ambulatory surgical centers. Angioplasty balloons are widely used in minimally invasive treatments for coronary artery disease, offering benefits such as improved blood flow restoration, reduced recovery time, and lower procedural risk.
• Market growth is driven by the increasing prevalence of cardiovascular diseases, rising geriatric population, and growing adoption of minimally invasive procedures. Additionally, improving healthcare infrastructure, expanding access to advanced medical technologies, and government initiatives to enhance cardiac care services are contributing significantly to the demand for angioplasty balloons in Mexico.
• The Scoring Balloons segment is expected to witness strong growth CAGR is 5.1% by 2026-2033 due to its effectiveness in reducing restenosis and minimizing the need for repeat procedures. Meanwhile, plain old balloon angioplasty (POBA) continues to hold a notable share owing to its cost-effectiveness and widespread use in basic angioplasty procedures, particularly in price-sensitive healthcare settings.
• Hospitals remain the dominant end-use segment in the Mexico angioplasty balloons market share is 47.50% in 2025, driven by the availability of advanced catheterization laboratories, skilled cardiologists, and higher patient inflow for cardiovascular treatments. The increasing number of private healthcare facilities and specialized cardiac centers is further supporting market expansion.
• Mexico is anticipated to experience steady growth within the Latin American angioplasty balloons market, supported by rising healthcare expenditure, increasing awareness of early cardiac treatment, and growing medical tourism. Technological advancements such as scoring balloons and cutting balloons are further enhancing procedural efficiency and clinical outcomes, strengthening market development over the forecast period.

Report Scope and Mexico Angioplasty Balloons Market Segmentation

Mexico Angioplasty Balloons Market Trends

“Integration Of Ai-Based Imaging In Angioplasty Procedures”

• The integration of AI-based imaging in angioplasty procedures represents a significant opportunity in the Mexico Angioplasty Balloons Market, as it enhances precision, efficiency, and clinical outcomes during cardiovascular interventions.
• Artificial intelligence-driven imaging systems assist interventional cardiologists by providing real-time, high-resolution visualization of blood vessels, plaque characteristics, and lesion severity. This enables more accurate selection of angioplasty balloon size, pressure, and positioning, thereby reducing procedural errors and improving patient safety.
• In Mexico, where the burden of coronary artery disease is rising, AI-assisted imaging can play a crucial role in optimizing treatment outcomes, especially in complex or high-risk cases. It also supports faster decision-making during procedures, which is critical in emergency cardiac interventions. Additionally, AI tools can help predict restenosis risk and guide post-procedure monitoring, improving long-term patient management.
• In December 2025, Philips’ acquisition of SpectraWAVE was announced by Royal Philips, aiming to strengthen AI-enabled coronary intravascular imaging and physiology assessment technologies. The deal integrates SpectraWAVE’s HyperVue imaging system and X1-FFR AI solution into Philips’ Azurion platform, enhancing image-guided angioplasty procedures. The acquisition expands AI-driven cardiac imaging capabilities and supports better clinical decision-making in coronary interventions, improving procedural precision and patient outcomes globally.
• In November 2025, GE HealthCare announced that it will acquire Intelerad for about $2.3 billion in cash. The deal, stated by GE HealthCare CEO Peter Arduini, aims to strengthen the company’s cloud-based imaging workflows and AI-enabled diagnostic platforms across hospitals and outpatient care settings. As highlighted by GE HealthCare, the integration combines its AI capabilities with Intelerad’s cloud imaging systems to improve efficiency, enable real-time image sharing, and support advanced cardiology and radiology workflows for precision-driven patient care.

Mexico Angioplasty Balloons Market Dynamics

Driver

Rising Prevalence of Cardiovascular Diseases In Mexico

• The rising prevalence of cardiovascular diseases (CVDs) in Mexico is a major driver for the angioplasty balloons market, as it directly increases the demand for interventional cardiac procedures.
• In recent years, Mexico has witnessed a growing burden of heart-related conditions such as coronary artery disease, atherosclerosis, and myocardial infarction, largely driven by lifestyle changes, sedentary habits, unhealthy dietary patterns, and increasing rates of obesity, diabetes, and hypertension. These risk factors are becoming more common across both urban and semi-urban populations, leading to a higher incidence of arterial blockages that require minimally invasive treatment.
• According to PAHO news published on December 2025, highlights those cardiovascular diseases such as heart disease and stroke cause more than 2.2 million deaths every year across the Americas, with countries like Mexico being significantly affected due to high rates of hypertension and other risk factors, which focuses on improving blood pressure control and preventing heart attacks and strokes through stronger primary healthcare systems. It also emphasizes that uncontrolled hypertension remains a major driver of cardiovascular mortality in the region.
• In February 2020, the PAHO/WHO HEARTS Initiative highlighted those cardiovascular diseases caused 141,619 deaths in Mexico in 2018, confirming the country’s significant and growing heart disease burden. This data was released by the Pan American Health Organization (PAHO) in collaboration with the World Health Organization (WHO) during the launch of the HEARTS initiative in Mexico. The initiative focuses on strengthening prevention and control of hypertension and cardiovascular conditions at the primary healthcare level.
• This high mortality figure reflects the increasing impact of lifestyle-related risks such as obesity, diabetes, and hypertension in Mexico, which further strengthens the need for advanced treatments like angioplasty balloon procedures.

Restraint/Challenge

High Cost Of Drug-Coated And Scoring Balloon Technologies

• The high cost of drug-coated and scoring balloon technologies acts as a significant restraint in the Mexico angioplasty balloons market. These advanced balloon systems are designed to improve treatment outcomes by reducing restenosis rates and enhancing lesion modification, but their pricing remains considerably higher than conventional plain old balloon angioplasty (POBA) devices.
• In Mexico, a large portion of cardiovascular procedures is performed in public hospitals and cost-sensitive healthcare settings, where budget limitations restrict the adoption of premium-priced medical devices.
• Even in private hospitals, reimbursement coverage for advanced angioplasty tools is often partial or inconsistent, forcing patients to bear out-of-pocket expenses. This financial burden limits widespread usage despite clinical advantages.
• In January 2025, the U.S. Centers for Medicare & Medicaid Services (CMS) approved an additional reimbursement support mechanism for procedures using Boston Scientific’s AGENT™ Drug-Coated Balloon (DCB). This decision was taken because standard hospital payment structures were not sufficient to fully cover the cost of the advanced device and associated procedure expenses. The CMS initiative highlights that drug-coated balloon technology carries a high baseline cost, requiring supplementary reimbursement to ensure hospital adoption.
• The news published on March 2024, by Boston Scientific Corporation states that the company received U.S. FDA approval for its AGENT Drug-Coated Balloon (DCB). This device is designed as a premium coronary intervention technology and serves as an advanced alternative to conventional balloon angioplasty for treating coronary in-stent restenosis. The announcement highlights that AGENT DCB is a drug-coated paclitaxel balloon catheter intended to improve clinical outcomes by preventing artery re-narrowing after stent placement.

Mexico Angioplasty Balloons Market Scope

Mexico Angioplasty Balloons Market is categorized into six notable segments which are based on type, material, balloon type, disease indication, end user, distribution channel.

• By Type

On the basis of Type, the Mexico Angioplasty Balloons Market is segmented into Plain Old Balloon Angioplasty, Drug-Coated Balloon (DCB), Scoring Balloons. Cutting Balloons, Stent Graft Balloon Catheter, and Others. In 2025, the Plain Old Balloon Angioplasty is expected to dominate the market share 37.50% due to its widespread clinical use, cost-effectiveness, and strong presence in public healthcare institutions where budget constraints favor conventional treatment options. Additionally, its versatility across multiple lesion types and procedural simplicity make it a preferred first-line intervention in a large volume of angioplasty procedures.

The Scoring Balloons is anticipated to show the fastest CAGR is 5.1% during the forecast period. The scoring balloons segment in the Mexico angioplasty balloons market is driven by increasing preference for precision-based lesion modification in complex vascular procedures. These balloons help reduce vessel trauma and improve controlled plaque disruption, supporting physician adoption for calcified and resistant lesions in minimally invasive interventions.

• By material

On the basis of material, the Mexico Angioplasty Balloons Market is segmented Nylon, Polyurethane, Silicone Urethane Co-Polymers, Polyethylene, Others. In 2025, the Nylon segment is expected to dominate the market share 47.60%. due to its superior tensile strength and high-pressure resistance, which enables precise and controlled balloon expansion in complex lesions. Additionally, its excellent balance between flexibility and durability enhances catheter trackability and procedural reliability, making it a preferred choice among interventional cardiologists.

Silicone Urethane Co-Polymers is anticipated to show the fastest CAGR is 4.9% during the forecast period. The silicone urethane co-polymers segment is driven by rising demand for advanced balloon materials offering flexibility, durability, and enhanced burst resistance. Manufacturers increasingly prefer these materials because they improve balloon performance, trackability, and procedural efficiency during cardiovascular and peripheral angioplasty procedures across healthcare facilities.

• By Balloon Type

On the basis of balloon type, the Mexico Angioplasty Balloons Market is segmented into Non-Compliant, Semi-Compliant, Compliant. In 2025, the Non-Compliant segment is expected to dominate the market share 44.54% due to its superior ability to deliver precise and high-pressure dilation in calcified and complex lesions, ensuring controlled expansion without over-stretching the vessel. Additionally, increasing adoption in advanced interventional procedures and preference among cardiologists for accurate lesion management further strengthens its market leadership.

Semi-Compliant is anticipated to show the fastest CAGR is 4.8% during the forecast period. The semi-compliant segment is driven by growing use in angioplasty procedures requiring controlled expansion and adaptability within vessels. Their capability to conform to varying vessel anatomy while maintaining procedural safety supports increasing demand among healthcare professionals performing interventional cardiovascular treatments in Mexico.

• By Disease Indication

On the basis of Disease Indication, the Mexico Angioplasty Balloons Market is segmented into Coronary Angioplasty, Peripheral Angioplasty, Carotid Angioplasty, Renal Artery Angioplasty, Venous Angioplasty, Others. In 2025, the Coronary Angioplasty segment is expected to dominate the market share 41.50%. due to the high prevalence of coronary artery disease in Mexico, driven by increasing rates of diabetes, obesity, and hypertension. Additionally, the widespread adoption of percutaneous coronary interventions in both public and private hospitals significantly contributes to higher procedural volumes within this segment.

Peripheral Angioplasty is anticipated to show the fastest CAGR is 4.8% during the forecast period. The peripheral angioplasty segment is driven by increasing prevalence of peripheral artery disease, diabetes, and lifestyle-related vascular disorders in Mexico. Rising awareness regarding minimally invasive treatments and growing procedural volumes in hospitals are supporting demand for specialized angioplasty balloons in peripheral interventions.

• By End User

On the baisis of End User, the Mexico Angioplasty Balloons Market is segmented into Hospitals, Cath Labs, Ambulatory Surgery Centers (ASCs), Specialty Clinics, Diagnostic Centers, Others. In 2025, the Hospitals segment is expected to dominate the market share 47.50%. due to the high volume of interventional cardiology procedures performed in both public and private hospital settings, supported by the availability of advanced infrastructure and skilled cardiologists. Additionally, hospitals serve as primary treatment centers for complex cardiovascular cases, ensuring consistent demand for angioplasty balloon devices across Tier I, Tier II, and Tier III facilities.

Ambulatory Surgery Centers (ASCs) is anticipated to show the fastest CAGR is 5.1% during the forecast period. The ambulatory surgery centers segment is driven by increasing preference for cost-effective and same-day vascular procedures. ASCs provide shorter hospital stays, reduced treatment expenses, and improved patient convenience, encouraging greater adoption of angioplasty procedures outside traditional hospital settings across Mexico.

• By Distribution Channel

On the basis of distribution Channel, the Mexico Angioplasty Balloons Market is segmented into Direct Tender, Retail Sales, Online Sales, Others. In 2025, the Direct Tender segment is expected to dominate the market share 71.70%. due to the high procurement volume of angioplasty devices by public healthcare institutions through centralized purchasing systems, ensuring cost efficiency and standardized supply. Additionally, government hospitals and large healthcare networks prefer direct tendering to secure bulk contracts from established medical device manufacturers, supporting consistent availability and pricing control.

Online Sales is anticipated to show the fastest CAGR is 4.7% during the forecast period. The online sales segment is driven by increasing digital procurement practices among healthcare providers and distributors. Expanding e-commerce penetration, streamlined purchasing platforms, and easier access to medical products support online channel growth, helping manufacturers enhance product availability and supply chain efficiency.

Mexico Angioplasty Balloons Market Regional Analysis

Mexico dominates the Mexico Angioplasty Balloons market with the largest revenue share in 2026, driven by advanced variants include drug-coated balloons, which deliver therapeutic agents to reduce restenosis, and cutting or scoring balloons designed for resistant lesions. Their use is critical in the treatment of coronary artery disease and peripheral artery disease, supporting improved patient outcomes and reduced need for invasive surgery.

Mexico Angioplasty Balloons Market Share

The Mexico Angioplasty Balloons Market is primarily led by well-established companies, including:

• Boston Scientific Corporation (U.S.)
• Medtronic (Ireland)
• Abbott (U.S.)
• Terumo Corporation (Japan)
• B. Braun (Germany)
• Teleflex Incorporated (U.S.)
• Cook Medical (U.S.)
• Biotronik (Germany)
• MicroPort Scientific Corporation (China)
• Sahajanand Medical Technologies (SMT) (India)
• Cordis (U.S.)
• OrbusNeich Medical Group Holdings Limited (Hong Kong)
• Invamed (Turkey)

Latest Developments in Mexico Angioplasty Balloons Market

• In September 2025, B. Braun Melsungen AG announced the acquisition of True Digital Surgery to strengthen its digital surgery capabilities. The move was intended to enhance advanced visualization and imaging technologies used in minimally invasive procedures, improve surgical precision, and support the company’s broader strategy of integrating digital innovation into its global healthcare solutions portfolio.
• In March 2025, Terumo Corporation outlined its long-term strategy, “Our Promise,” emphasizing the strengthening of global innovation capabilities. The initiative focuses on advancing cardiovascular technologies, enhancing research and development efficiency, and accelerating the delivery of high-quality medical solutions worldwide, thereby reinforcing Terumo’s commitment to improving patient outcomes and expanding its presence across key international healthcare markets.
• In March 2026, clinical data from interventional cardiology trials highlighted the growing adoption of drug-coated balloons (DCBs)—a segment where Abbott is an active player. These studies showed that DCBs significantly reduce repeat procedures compared to conventional angioplasty balloons, reinforcing their clinical value.
• In April 2026, Medtronic reported positive real-world outcomes for its IN.PACT AV drug-coated balloon, confirming its safety and effectiveness in treating vascular access sites. The data indicated improved vessel patency and reduced need for repeat interventions, reinforcing the device’s value in managing dialysis-related complications and supporting its broader adoption in interventional vascular procedures.

SKU-75915